Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal

Stock Track04-14

XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.

The sharp rise follows the company's announcement that it has received formal approval from the China Securities Regulatory Commission for the conversion of 357 million non-tradable shares into H-shares. This H-share reform is expected to substantially expand the company's tradable share base and lead to a fundamental improvement in liquidity.

Additionally, the company recently entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, XUANZHUBIO-B granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa and is expected to receive an upfront payment plus cumulative milestone payments exceeding $100 million, along with royalties based on sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132796697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 14:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132796697","market":"nz","top_or_hot":-1,"title":"Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal","media":"Stock Track","content":"<p>XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise follows the company's announcement that it has received formal approval from the China Securities Regulatory Commission for the conversion of 357 million non-tradable shares into H-shares. This H-share reform is expected to substantially expand the company's tradable share base and lead to a fundamental improvement in liquidity.</p><p>Additionally, the company recently entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, XUANZHUBIO-B granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa and is expected to receive an upfront payment plus cumulative milestone payments exceeding $100 million, along with royalties based on sales.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | XUANZHUBIO-B Soars 12.58% in Afternoon Trading on H-Share Reform Approval and Lucrative Drug Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-14 14:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise follows the company's announcement that it has received formal approval from the China Securities Regulatory Commission for the conversion of 357 million non-tradable shares into H-shares. This H-share reform is expected to substantially expand the company's tradable share base and lead to a fundamental improvement in liquidity.</p><p>Additionally, the company recently entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, XUANZHUBIO-B granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa and is expected to receive an upfront payment plus cumulative milestone payments exceeding $100 million, along with royalties based on sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1132796697","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132796697","pubTimestamp":1776147162,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The sharp rise follows the company's announcement that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"个股赛道|轩竹生物-B午后大涨12.58%受H股改革批文及利润丰厚的药品授权交易影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XUANZHUBIO-B's stock surged 12.58% during afternoon trading on Tuesday, marking a significant upward movement for the biopharmaceutical company.The sharp rise follows the company's announcement that it has received formal approval from the China Securities Regulatory Commission for the conversion of 357 million non-tradable shares into H-shares. This H-share reform is expected to substantially expand the company's tradable share base and lead to a fundamental improvement in liquidity.Additionally, the company recently entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, XUANZHUBIO-B granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa and is expected to receive an upfront payment plus cumulative milestone payments exceeding $100 million, along with royalties based on sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132796697","isCrawlerRequest":true}